Hoth Therapeutics Inc (HOTH)

Apr 14, 2026, 12:30 PM EDT - 14 days ago

Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug

Apr 14, 2026, 7:00 AM EDT - 14 days ago

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Apr 2, 2026, 4:05 PM EDT - 26 days ago

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Apr 1, 2026, 1:52 PM EDT - 27 days ago

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Apr 1, 2026, 8:14 AM EDT - 27 days ago

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Mar 31, 2026, 8:07 AM EDT - 4 weeks ago

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Mar 26, 2026, 8:30 AM EDT - 4 weeks ago

Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Mar 24, 2026, 8:13 AM EDT - 5 weeks ago

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Mar 10, 2026, 8:13 AM EDT - 7 weeks ago

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Mar 4, 2026, 8:31 AM EST - 7 weeks ago

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Feb 24, 2026, 4:15 PM EST - 2 months ago

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Feb 10, 2026, 8:30 AM EST - 2 months ago

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Feb 10, 2026, 8:01 AM EST - 2 months ago

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Feb 5, 2026, 8:03 AM EST - 2 months ago

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Jan 22, 2026, 8:13 AM EST - 3 months ago

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Jan 21, 2026, 8:13 AM EST - 3 months ago

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Jan 15, 2026, 8:17 AM EST - 3 months ago

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Jan 2, 2026, 8:13 AM EST - 4 months ago

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Dec 3, 2025, 2:00 PM EST - 5 months ago

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Dec 1, 2025, 8:03 AM EST - 5 months ago

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Nov 20, 2025, 8:13 AM EST - 5 months ago

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Oct 27, 2025, 7:49 AM EDT - 6 months ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 21, 2025, 8:23 AM EDT - 6 months ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 8, 2025, 8:02 AM EDT - 7 months ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 7, 2025, 7:57 AM EDT - 7 months ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Sep 24, 2025, 8:13 AM EDT - 7 months ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 16, 2025, 8:14 AM EDT - 8 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 10, 2025, 8:29 AM EDT - 8 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 4, 2025, 8:16 AM EDT - 8 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 2, 2025, 8:16 AM EDT - 8 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Jul 29, 2025, 7:58 AM EDT - 9 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 22, 2025, 8:19 AM EDT - 10 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jun 25, 2025, 8:27 AM EDT - 10 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Jun 24, 2025, 10:36 AM EDT - 11 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 23, 2025, 8:03 AM EDT - 11 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 18, 2025, 1:34 PM EDT - 11 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 8:22 AM EDT - 11 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 12, 2025, 9:17 AM EDT - 11 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 11, 2025, 8:28 AM EDT - 11 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 11 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

May 12, 2025, 7:30 AM EDT - 1 year ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Apr 17, 2025, 8:01 AM EDT - 1 year ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 15, 2025, 8:19 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 2, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 7:58 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Mar 31, 2025, 4:45 PM EDT - 1 year ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 26, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 18, 2025, 8:06 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 10, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need